Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 11 of 11

List	Outcome	Time frame	Description
Primary	DLT	up to week 6	Number of patients with dose limiting toxicity
Primary	TEAEs	up to approximately 2 years	Number of patients with treatment-emergent adverse events
Primary	AEs	up to approximately 2 years	Number of patients with treatment-related Adverse Events
Secondary	ORR	up to approximately 2 years	Objective Response Rate
Secondary	DOR	up to approximately 2 years	Duration of response
Secondary	DCR	up to approximately 2 years	Disease control rate
Secondary	PFS	up to approximately 2 years	Progression Free survival
Secondary	OS	up to approximately 2 years	Overall Survival
Other	AUC	up to approximately 2 years	Area Under Curve
Other	Cmax	up to approximately 2 years	Maximum concentration
Other	The correlation of biomarkers with efficacy	up to approximately 2 years	The correlation of PIK3CA, AKT mutations, TMB and PD-L1 expression and other biomarkers with the efficacy of duvelisib will be assessed.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05508659/registered